<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887820</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16060542</org_study_id>
    <nct_id>NCT02887820</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)</brief_title>
  <official_title>A Pilot Study in Feasibility and Safety: Point of Care Testing With Thromboelastography (TEG) for Blood Product Transfusion in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephen Esper</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study that seeks to evaluate the feasibility and safety of using a TEG
      algorithm in addition to traditional laboratory tests to guide transfusion and coagulation
      management of ECMO patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All adult patients requiring ECMO will be considered for the trial, with a target enrollment
      of 50 participants over a two-year period. For each enrolled participant, a TEG transfusion
      algorithm will be followed for patients exhibiting inadequate hemostasis in the operating
      room (Flowchart 1). Once patient has a normal TEG result with adequate hemostasis, either
      heparin or bivalirudin will be used as the anticoagulant. If patients are receiving no
      anticoagulation or heparin anticoagulation then a second TEG algorithm will be followed in
      the ICU when hemostasis is normal and heparin is introduced (Flowchart 2). If patients are
      receiving bivalirudin as their anticoagulation strategy, the transfusion parameters with TEG
      application will not apply. In addition to determining the compliance and feasibility of
      following these TEG algorithms, clinical outcome data including transfusion rates, types of
      blood products transfused, estimated blood loss and thrombotic events will be collected for
      every enrolled patient until they are discontinued from ECMO. Statistical analysis of the
      primary, secondary and tertiary endpoints of this study will determine the likelihood of
      exploring future clinical trials involving TEG-driven coagulation and transfusion management
      of the ECMO population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants whose blood management care follows a TEG algorithm 90% of the time</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions required while on ECMO</measure>
    <time_frame>From the time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that experience bleeding or thrombotic-related adverse events, including deep venous thrombosis or pulmonary embolus</measure>
    <time_frame>From the time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest tube output and overall estimated blood loss</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between transfusions</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of blood products transfused</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pump exchanges required</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenator exchanges</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of pump circuit clotting and clots in the oxygenator (visible clot which did not require circuit/pump exchange)</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to weaning from/removal of ECMO</measure>
    <time_frame>From time patient is placed on ECMO until time to weaning from ECMO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical intervention for hemorrhage</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen turn around time for lab tests (CBC, ACT, PT, PTT, anti-Xa, INR, platelet count) and TEG results</measure>
    <time_frame>From time patient is placed on ECMO to 30-days post ECMO initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Disease</condition>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>Pilot Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thromboelastograph</intervention_name>
    <description>A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions</description>
    <arm_group_label>Pilot Arm</arm_group_label>
    <other_name>TEG 5000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's requiring ECMO placement

        Exclusion Criteria:

          -  Other than children less than 18 years of age, no one will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Esper, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy L Monroe, BS</last_name>
    <phone>412-609-6161</phone>
    <email>monroeal@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy L Monroe, BS</last_name>
      <phone>412-609-6161</phone>
      <email>monroeal@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathirvel Subramaniam, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur J Boujoukos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boisen Michael, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Esper, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>D'Cunha Jonathan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hayanga Jeremiah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kormos Robert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lagazzi Luigi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sappington Penny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Triulzi Darrell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Waters Jonathan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009 Sep;13(3):154-75. doi: 10.1177/1089253209347384. Review.</citation>
    <PMID>19767408</PMID>
  </results_reference>
  <results_reference>
    <citation>Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5-6):321-7. Review.</citation>
    <PMID>15507261</PMID>
  </results_reference>
  <results_reference>
    <citation>Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs. 1999 Nov;23(11):979-83.</citation>
    <PMID>10564301</PMID>
  </results_reference>
  <results_reference>
    <citation>Colby CE, Sheehan A, Benitz W, Van Meurs K, Halamek LP, Moss RL. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400. J Extra Corpor Technol. 2003 Mar;35(1):35-8.</citation>
    <PMID>12680494</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn. 1994 May;32(1):49-52.</citation>
    <PMID>8039220</PMID>
  </results_reference>
  <results_reference>
    <citation>Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994 Dec;108(6):1076-82.</citation>
    <PMID>7983877</PMID>
  </results_reference>
  <results_reference>
    <citation>Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007871. doi: 10.1002/14651858.CD007871.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD007871.</citation>
    <PMID>21412912</PMID>
  </results_reference>
  <results_reference>
    <citation>Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999 Feb;88(2):312-9.</citation>
    <PMID>9972747</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Stephen Esper</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology, Chief of Perioperative Services</investigator_title>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>TEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

